We can’t show the full text here under this license.
Abstract
Preliminary data suggest that psilocybin and may be effective in treating several psychiatric conditions.
- drugs like psilocybin and MDMA have been reconsidered in psychiatric research after a long period of prohibition.
- Research indicates promising results for psilocybin in treating anxiety, depression, and alcoholism.
- MDMA shows potential in treating post-traumatic stress disorder (PTSD) and alcoholism.
- The European Medicines Agency has approved psilocybin for a phase 3 study in treatment-resistant depression.
- The Food and Drug Administration has approved MDMA for a phase 3 study in PTSD.
- Positive outcomes from these trials could lead to clinical approval of these substances.
Simplified